Page last updated: 2024-09-04

atractylenolide iii and etoposide

atractylenolide iii has been researched along with etoposide in 1 studies

Compound Research Comparison

Studies
(atractylenolide iii)
Trials
(atractylenolide iii)
Recent Studies (post-2010)
(atractylenolide iii)
Studies
(etoposide)
Trials
(etoposide)
Recent Studies (post-2010) (etoposide)
8606218,3063,6934,900

Protein Interaction Comparison

ProteinTaxonomyatractylenolide iii (IC50)etoposide (IC50)
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]Homo sapiens (human)1.153
nuclear receptor coactivator 3 isoform aHomo sapiens (human)1.4284
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)3.187
Caspase-3Homo sapiens (human)1
DNA topoisomerase 2-betaHomo sapiens (human)0.4299
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)4.18

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gu, Y; Liu, H; Qi, L; Wu, H; Wu, L; Xiao, L; Zhang, L; Zhang, M1

Other Studies

1 other study(ies) available for atractylenolide iii and etoposide

ArticleYear
Atractylenolide III suppresses senescence-associated secretome via inhibiting cGAS/NF-κB pathway in hepatic stellate cells.
    Clinical and experimental pharmacology & physiology, 2023, Volume: 50, Issue:4

    Topics: Cellular Senescence; Etoposide; Hepatic Stellate Cells; Humans; Liver Cirrhosis; NF-kappa B; Nucleotidyltransferases; Secretome

2023